Ph+ ALL chemo with targeted pills and transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You have a type of acute lymphoblastic leukemia (ALL) with the Philadelphia chromosome or BCR-ABL1 gene change
- You have not had chemotherapy or targeted pills (like imatinib or ponatinib) for this leukemia before (except for a few days of steroids or initial treatment)
- Your overall health allows you to do daily activities without significant help (ECOG 0-2)
- Your heart, kidney, and liver function are within safe limits (no active heart disease, prior stroke, or pancreatic problems)
- You are willing to use two effective forms of birth control during and for 3 months after treatment (if applicable)
- You agree to join the German ALL study group registry
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see how well the treatment works and to manage the disease, with some patients also receiving a stem cell transplant.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This trial tests a combination of two drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This study tests a combination of a lower-dose chemotherapy and a short course of an immunotherapy drug called blinatumomab, before a stem cell transplant, to see if it helps improve outcomes for adults with certain types of ALL.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
Hear when a new Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.